| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,760,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Castle Biosciences is a commercial-stage dermatological diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Co.'s main product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. Co. has commercially launched its cutaneous squamous cell carcinoma (SCC) proprietary GEP test, DecisionDx®-SCC, for use in patients with one or more risk factors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
4,800 |
5,962 |
| Total Buy Value |
$0 |
$0 |
$69,004 |
$93,987 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
112,148 |
353,441 |
444,414 |
787,882 |
| Total Sell Value |
$2,473,680 |
$7,495,938 |
$9,336,823 |
$17,895,563 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
22 |
80 |
92 |
181 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-05-15 |
4 |
AS |
$23.45 |
$36,061 |
D/D |
(1,538) |
150,443 |
|
- |
|
| Olson Tiffany |
Director |
– • – |
2023-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
487 |
3,455 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-05-05 |
4 |
AS |
$21.12 |
$158,078 |
I/I |
(7,357) |
77,805 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-05-04 |
4 |
AS |
$21.43 |
$120,734 |
I/I |
(5,580) |
20,212 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-05-04 |
4 |
AS |
$21.43 |
$60,410 |
D/D |
(2,792) |
151,981 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-05-04 |
4 |
AS |
$21.29 |
$382,668 |
I/I |
(17,643) |
79,276 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-13 |
4 |
AS |
$22.68 |
$82,635 |
I/I |
(3,644) |
20,908 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-13 |
4 |
AS |
$22.68 |
$41,340 |
D/D |
(1,823) |
154,773 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-12 |
4 |
AS |
$22.61 |
$43,777 |
I/I |
(1,936) |
21,363 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-12 |
4 |
AS |
$22.61 |
$21,911 |
D/D |
(969) |
156,596 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-04-05 |
4 |
AS |
$22.20 |
$157,620 |
I/I |
(7,100) |
82,805 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-04-04 |
4 |
AS |
$22.19 |
$168,614 |
I/I |
(7,600) |
84,225 |
|
- |
|
| Stokes Frank |
Chief Financial Officer |
• – – |
2023-04-04 |
4 |
OE |
$3.38 |
$13,520 |
D/D |
4,000 |
23,419 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-04 |
4 |
AS |
$22.10 |
$17,703 |
I/I |
(801) |
21,605 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-04 |
4 |
AS |
$22.10 |
$8,863 |
D/D |
(401) |
157,565 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-04-03 |
4 |
AS |
$22.14 |
$227,991 |
I/I |
(10,300) |
85,745 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-03 |
4 |
AS |
$22.15 |
$105,836 |
I/I |
(4,779) |
21,705 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-04-03 |
4 |
AS |
$22.15 |
$52,951 |
D/D |
(2,391) |
157,966 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-03-14 |
4 |
AS |
$20.95 |
$116,923 |
I/I |
(5,580) |
22,302 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-03-14 |
4 |
AS |
$20.95 |
$58,504 |
D/D |
(2,792) |
160,357 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-03-06 |
4 |
AS |
$24.71 |
$137,871 |
I/I |
(5,580) |
22,999 |
|
- |
|
| Maetzold Derek J |
Pres. & Chief Exec. Officer |
• • – |
2023-03-06 |
4 |
AS |
$24.71 |
$68,985 |
D/D |
(2,792) |
163,149 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-03-03 |
4 |
AS |
$24.53 |
$334,859 |
I/I |
(13,651) |
87,805 |
|
- |
|
| Bradbury Daniel |
Director |
– • – |
2023-03-02 |
4 |
AS |
$23.16 |
$264,411 |
I/I |
(11,349) |
90,535 |
|
- |
|
| Juvenal Tobin W |
Chief Commercial Officer |
• – – |
2023-03-01 |
4 |
OE |
$2.39 |
$14,753 |
D/D |
6,173 |
22,092 |
|
- |
|
627 Records found
|
|
Page 6 of 26 |
|
|
